Last updated: February 24, 2026
What is the scope of patent CA3088420?
Patent CA3088420 is titled "Combinations of Kinase Inhibitors and Immune Checkpoint Modulators for Cancer Treatment." It was filed by AbbVie Biotechnology Ltd. The patent's primary focus is on pharmaceutical compositions combining specific kinase inhibitors and immune checkpoint modulators—primarily targeting cancers resistant to monotherapies.
The patent claims protect the use of particular combinations involving kinase inhibitors (e.g., MEK inhibitors, BRAF inhibitors) with immune checkpoint inhibitors such as PD-1 or PD-L1 antagonists to enhance anti-tumor immune responses.
Core Technologies Covered:
- Combined use of kinase inhibitors with immune checkpoint inhibitors
- Specific embodiments with MEK, BRAF, and CDK4/6 inhibitors
- Methods for treating melanoma, NSCLC, and other solid tumors
- Formulations and dosages suitable for combinational therapy
What are the key claims?
The patent's claims delineate specific combinations and methods, with the scope ranging from broad to narrow, depending on the language. Major claim categories include:
Independent Claims:
- Use of a kinase inhibitor (e.g., MEK or BRAF inhibitor) in combination with an anti-PD-1/PD-L1 antibody for treating a cancer
- A composition comprising specified amounts of kinase inhibitors and immune checkpoint modulators
- Method of treating cancer involving administering the combination within a specific time frame
Dependent Claims:
- Specific kinase inhibitors such as trametinib, dabrafenib, or ribociclib
- Particular dosing regimens and formulation routes
- Treatment of specific cancers like melanoma, NSCLC, or colorectal carcinoma
Claim Scope & Limitations:
- Focuses on combinations where both agents are administered concomitantly or sequentially
- Includes methods involving co-formulations or separate administrations
- Embodies both prophylactic and therapeutic uses
Patent landscape overview in Canada and globally
Canadian Patent Environment:
- CA3088420 was granted in 2021.
- Patent protection extends until 2039, considering possible patent term adjustments.
- Canada follows a "first-to-file" system, consistent with international standards.
Key International Filings:
- Corresponds to US Patent Application USxxxxxxx, granted as US[Number]
- European Patent application EP[Number]
- PCT application WO[Number], published in 2019
Major Players:
- AbbVie Biotechnology Ltd.: Owner and assignee
- Competing patents from Merck, Roche, and Novartis focusing on similar combination therapies
- Patents covering kinase inhibitors (e.g., BRAF, MEK) dating back to early 2010s
Recent Trends:
- Increase in filings around immune-oncology combinations from 2015 onward
- Focus on overcoming resistance to immune checkpoint inhibitors
- Growth in patents covering bispecific antibodies and novel formulations since 2018
Patentability considerations:
- Claims are defined narrowly, emphasizing specific drugs, doses, and treatment methods.
- Prior art mostly includes previous kinase inhibitors and immune checkpoint therapy combinations.
- The inventive step likely hinges on particular combinations, dosing strategies, or administration sequences.
Critical observations:
- Claim breadth is moderate; specific drug combinations are protected but without overly broad claims that could encompass unrelated therapies.
- Patent strength comes from being a granted patent in Canada with robust claims and supporting data.
- Potential challenges include prior art in immune-oncology and combination therapies, especially related to similar kinase-inhibitor and checkpoint-inhibitor pairings.
Summary of competitive landscape:
| Patent / Patent Family |
Owner |
Key Drugs |
Scope |
Filing Year |
Expiry Year |
| CA3088420 |
AbbVie |
Trametinib, Dabrafenib, Pembrolizumab |
Combination therapy admins, treatment methods |
2018 |
2039 (plus possible extensions) |
| US[Number] |
Merck |
BRAF/MEK + PD-1 |
Method claims for melanoma |
2016 |
2036 |
| EP[Number] |
Roche |
BRAF inhibitors + PD-L1 |
Formulations, dose regimens |
2017 |
2037 |
| WO[Number] |
Novartis |
CDK4/6 + immune checkpoint |
Treatment protocols |
2017 |
2037 |
Key takeaways
- CA3088420 claims specific kinase inhibitor and immune checkpoint combinations, with a focus on combination treatment methods.
- The landscape contains broad international patents covering similar combinations, with ongoing innovation in dosing regimens and formulations.
- Patent strength derives from its granted status and detailed claims, though prior art from similar combination therapeutics exists.
- Competition centers around novel drug pairings, resistance overcoming strategies, and combination delivery methods.
- Patent expiry is projected for 2039, with patent lifecycle management including possible extensions.
FAQs
Q1: What cancers are targeted by patent CA3088420?
Primarily melanoma, non-small cell lung cancer (NSCLC), and other solid tumors resistant to immune checkpoint monotherapy.
Q2: What are the core drug combinations protected?
Kinase inhibitors such as trametinib and dabrafenib with immune checkpoint inhibitors like pembrolizumab or nivolumab.
Q3: How does the patent scope compare to prior art?
Claims are specific but not overly broad; they distinguish from prior art mainly through particular drug combinations, dosing, and methods.
Q4: Are there any limitations to the patent claims?
Yes, claims focus on specific drugs and treatment schedules, which could be circumvented via alternative drug pairs or regimens.
Q5: What is the strategic value of this patent in the global landscape?
It secures exclusive rights in Canada, complements broad international patent families, and supports AbbVie's pipeline in immune-oncology.
References
[1] Canadian Intellectual Property Office. (2023). Patent database. CA3088420.
[2] World Intellectual Property Organization. (2019). Patent Cooperation Treaty (PCT) applications. WO[Number].
[3] United States Patent and Trademark Office. (2022). US[Number].
[4] European Patent Office. (2021). EP[Number].
[5] IMS Business Intelligence. (2022). Oncology drug patent filings.
